Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €9.78 EUR
Change Today -0.126 / -1.27%
Volume 0.0
AM6 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 6:07 AM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (AM6) Snapshot

Open
€10.04
Previous Close
€9.90
Day High
€10.04
Day Low
€9.76
52 Week High
03/19/15 - €12.34
52 Week Low
04/17/14 - €1.29
Market Cap
934.7M
Average Volume 10 Days
356.4
EPS TTM
--
Shares Outstanding
95.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMICUS THERAPEUTICS INC (AM6)

amicus therapeutics inc (AM6) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (AM6) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs include next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has completed two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson's disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

97 Employees
Last Reported Date: 03/3/15
Founded in 2002

amicus therapeutics inc (AM6) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $824.1K
President and Chief Operating Officer
Total Annual Compensation: $475.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $445.1K
Compensation as of Fiscal Year 2013.

amicus therapeutics inc (AM6) Key Developments

Amicus Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Cash Spend Guidance for the Year of 2015

Amicus Therapeutics, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported loss from operations of $21.997 million compared to $15.790 million a year ago. Loss before tax was $22.332 million compared to $15.749 million a year ago. Net loss attributable to common stockholders was $21.219 million or $0.24 per basic and diluted share compared to $12.237 million or $0.22 per basic and diluted share a year ago. For the year, the company reported total revenue of $1.224 million compared to $0.363 million a year ago. Loss from operations was $68.701 million compared to $64.181 million a year ago. Loss before tax was $70.039 million compared to $63.145 million a year ago. Net loss attributable to common stockholders was $68.926 million or $0.93 per basic and diluted share compared to $59.633 million or $1.16 per basic and diluted share a year ago. Net cash spend was $53.2 million. The narrower net loss per share versus the year-ago period is attributed to an increase in the shares outstanding as a result of ATM and follow-on public offerings. The company expects full-year 2015 net cash spend between $73 million and $83 million.

Amicus Therapeutics Seeks Acquisitions

Amicus Therapeutics, Inc. (NasdaqGM:FOLD) stated in its Form S-3 filed on March 3, 2015 that, except as otherwise provided in the applicable prospectus supplement relating to a specific offering, they intend to use the net proceeds from the sale of securities by us under this prospectus for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures, clinical trial expenditures, commercial expenditures, acquisitions of new technologies or businesses, and investments. Additional information on the use of net proceeds from the sale of securities under this prospectus may be set forth in the prospectus supplement relating to the specific offering.

Amicus Therapeutics, Inc. to Report Fiscal Year 2014 Results on Mar 03, 2015

Amicus Therapeutics, Inc. announced that they will report fiscal year 2014 results on Mar 03, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AM6:GR €9.78 EUR -0.126

AM6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AM6.
View Industry Companies
 

Industry Analysis

AM6

Industry Average

Valuation AM6 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 778.6x
Price/Book 8.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 720.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit www.amicustherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.